Navigation Links
IDO2 an active enzyme to target in pancreatic cancer
Date:12/1/2008

(PHILADELPHIA) An enzyme that is overexpressed in pancreatic cancer cells may hold the key to successfully treating the disease with targeted immunotherapy, researchers from Thomas Jefferson University reported at the 2008 Annual Meeting of the Southern Surgical Association.

Previous data show that a protein, indoleamine 2,3-dioxygenase (IDO), is overexpressed in pancreatic ductal adenocarcinomas, according to Jonathan R. Brody, Ph.D., an assistant professor in the Department of Surgery at Jefferson Medical College of Thomas Jefferson University in Philadelphia, and co-director of the Jefferson Center for Pancreas, Biliary and Related Cancers. The center is led by Charles J. Yeo, M.D., Samuel D. Gross Professor and chair of the Department of Surgery, who was also involved with the study.

According to Dr. Brody, IDO is an enzyme that represses the immune system, thus protecting the cancer cells and helping them evade immune detection. The Jefferson researchers and their collaborators from the Lankenau Institute for Medical Research (LIMR) in Wynnewood, Pa., previously reported that the IDO inhibitor D-1-methyl-tryptophan (1-MT), preferentially targets a related protein, IDO2.

"Our data are the first that report expression of the IDO2 protein in malignant pancreatic tissue," Dr. Brody said. "About 75 percent of the patients in our cohort have an active enzyme based on genetic analysis. This puts forth the concept of genotyping patients for the IDO2 enzyme, to identify patients who may respond to a therapeutic strategy including an IDO inhibitor, a potential novel drug for pancreatic cancer."

Dr. Brody and his team, which included George Prendergast, Ph.D., and Richard Metz, Ph.D., from LIMR, sequenced IDO2 in 36 resected pancreatic ductal adenocarcinomas to evaluate how many patients harbor an active enzyme in relation to well-known polymorphisms: R235W and Y359STOP. Presumably, only one functional allele needs to be present in order to have an active IDO2 enzyme.

Nineteen percent of the patients were homozygous wild-type, meaning they had two active alleles, and 42 percent of the patients were heterozygous, meaning they had one active allele. Twenty-five percent were homozygous for two inactive IDO2 alleles. The remaining 14 percent were difficult to determine due to limits in sequencing and distinguishing the alleles, but were most likely heterozygous, according to Dr. Brody.

Phase-1 studies of 1-MT, the IDO inhibitor are currently underway.


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
2. USA-ONE Interactive Announces Document Management Solutions That Meet the Needs of Individual Industries
3. TeleHealth Services TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center
4. Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein
5. Boomers Play an Active Role with Parent's Medication Decisions
6. Active Young Women Need Calcium, Vitamin D
7. The HealthCentral Networks MyDiabetesCentral.com Launches Interactive Resource to Promote Awareness of Diabetes
8. iTech Fitness Taps Metzger for National Active Gaming Campaign
9. Virgin Active Says Leave the Cleavage to the Girls
10. LodgeNet Interactive to Report Third Quarter Results on October 28th
11. MyHealthGate, Inc. Joins With LiveActive Chewy Granola Bars to Raise Digestive Health Awareness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... TX (PRWEB) , ... February 24, 2017 , ... ... offering promotions on tooth replacement options at his office, Antoine Dental Center. Currently, ... implants for $18,499. Some restrictions may apply, but patients can learn more about ...
(Date:2/24/2017)... PA (PRWEB) , ... February 24, 2017 , ... An ... researchers at the University of Pittsburgh points to eight genes that may explain why ... other, according to the results of a study published today in the journal npj ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT ... top priority because it’s not if you will be attacked, but when.” However, he ... comes to digital health care. , Improvements in auditing and monitoring have taken security ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ ... Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he ... and his attempts to overcome them. , Schanssema, initially unsure of the career path ...
(Date:2/24/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... Yisrayl makes an astounding statement when he says that the entire Bible was written ... the current times so plainly that anyone should be able to see the time ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... BRISBANE, Australia , Feb. 23, 2017  Directors from Pharma ... the two companies have joined forces, resulting in the founding of ... . Pharma To Market are pleased to announce their ... an office in Singapore . The company are ... Consulting as Co-Director of the Singapore based ...
(Date:2/24/2017)... YORK , Feb. 23, 2017 /PRNewswire/ ... comprehensive insights on the various drugs being ... report covers all the drugs that are ... & Clinical). The pipeline focuses on novel ... molecules, antibodies, stem cell therapies, recombinant proteins ...
(Date:2/24/2017)... Medivir AB (Nasdaq Stockholm: MVIR) today announced ... Directors that will be submitted to the 2017 Annual ... the company,s three largest shareholders at the end of ... seat on the Nomination Committee, and the Chairman of ... was as follows:  Anders ...
Breaking Medicine Technology: